Atopic Dermatitis (Atopic Eczema) – Pipeline Review, H2 2018 – Pharmaceuticals Market Research

PUNE, India, August 30, 2018 /ResearchByMarkets/— “Atopic Dermatitis (Atopic Eczema) – Pipeline Review, H2 2018, provides an overview of the Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

REQUEST A SAMPLE REPORT:
https://www.researchbymarkets.com/sample-request/32974

Report Highlights

Atopic Dermatitis (Atopic Eczema) – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Atopic Eczema) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 42, 20, 1, 46, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 4 and 2 molecules, respectively.

Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Atopic Eczema) (Dermatology).
– The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Atopic Eczema) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Atopic Dermatitis (Atopic Eczema) (Dermatology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Atopic Dermatitis (Atopic Eczema) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Atopic Eczema) (Dermatology)

ASK SPECIFIC QUERIES ABOUT THIS REPORT:
https://www.researchbymarkets.com/inquiry/32974

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Atopic Eczema) (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

GET A COPY OF THIS REPORT:
https://www.researchbymarkets.com/paynow/32974

Companies Mentioned:
AbbVie Inc
Abeome Corp
Accolade Pharmaceuticals LLC
Aclaris Therapeutics Inc
Allergan Plc
Almirall SA
Amgen Inc
Amorepacific Corp
AnaptysBio Inc
AntibioTx AS
Asana BioSciences LLC
Aslan Pharmaceuticals Pte Ltd
Bausch Health Companies Inc
Bioleaders Corp
Blueberry Therapeutics Ltd
Celgene Corp
ChironWells GmbH
Chugai Pharmaceutical Co Ltd
Clevexel Pharma SAS
Cutanea Life Sciences Inc
Dermala Inc
DURECT Corp
Eli Lilly and Co
Evelo Biosciences Inc
Evotec AG
F. Hoffmann-La Roche Ltd
Fountain Biopharma Inc
Galapagos NV
Galderma SA
Galectin Therapeutics Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Golden Biotechnology Corp
Han Wha Pharma Co Ltd
Heptares Therapeutics Ltd
iCo Therapeutics Inc
Immune Pharmaceuticals Inc
Incyte Corp
Inflamalps SA
Innovation Pharmaceuticals Inc
Japan Tobacco Inc
JW Pharmaceutical Corp
Kang Stem Biotech Co Ltd
Kv1.3 Therapeutics
Kyowa Hakko Kirin Co Ltd
Lead Pharma Holding BV
LEO Pharma A/S
Madam Therapeutics BV
Medicenna Therapeutics Corp
MedImmune LLC
NeoPharm Co Ltd
NeuroCycle Therapeutics GmbH
Novan Inc
Novartis AG
Nuevolution AB
OliX Pharmaceuticals Inc
Orbis Biosciences Inc
Otsuka Holdings Co Ltd
Pfizer Inc
Pharmedartis GmbH
Portola Pharmaceuticals Inc
Provectus Biopharmaceuticals Inc
Qurient Co Ltd
Realm Therapeutics Plc
Regeneron Pharmaceuticals Inc
Ribomic Inc
Sienna Biopharmaceuticals Inc
Signum Biosciences Inc
Spherium Biomed SL
sterna biologicals Gmbh & Co KG
TaiwanJ Pharmaceuticals Co Ltd
The Geneva Biotech Center SA
Torrent Pharmaceuticals Ltd
VivaCell Biotechnology Espana SL

Get in touch with us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com/aboutus

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.